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INTRODUCTION 
Methotrexate (MTX) is one of the most widely used oncocytotopic drugs1. Recently it has been used in
extremely high doses (8-15 gms/m2) in the treatment of osteosarcoma2, non-Hodgkin’s lymphoma and
metastatic head and neck cancer3. Such high doses facilitate the passive entry of MTX in most solid
tumours and thereby provide the necessary tumour cell kill. However, to achieve the desired effects of
this treatment, it is usually given repeatedly over extended periods of time depending upon the type of
regimen being followed. Toxicity of the drug is prevented by ensuring its rapid clearance from the body
by proper hydration, alkalinization and restoring to leucovorin "rescue"4. However, reports of delayed
plasma clearance of the drug during the course of therapy in certain patients with osteosarcoma due to
one reason or another and the ensuing toxicity are not very uncommon5,6. We report a patient suffering
from osteosarcoma who developed severe toxicity following third infusion of MDC due to delayed
plasma clearance of the drug.
CASE REPORT 
A 19 year old male was admitted to The Aga Khan University Hospital with pain and tenderness in the
left knee. Incisional biopsy from the lower end of the femur established the diagnosis of osteogenic
sarcoma. Radiological examination of liver and chest indicated no evidence of metastasis. The patient
was put on chemotherapy and was first given a course with cyclophosphamide- bleomycin-adriamycin
and then two weeks later put on high dose MTX therapy (12 gm/m2 every week). In every cycle of
treatment, MTX (18.7 gm) was administered in the form of 6-hr infusion. This therapy was
discontinued after the third MDC infusion as he developed symptoms of severe toxicity which included
fever, chills, nausea, vomiting, maceration of skin, erythema, pancytopenia, etc. During chemotherapy,
serum creatinine levels remained almost within the normal range. MIX levels in plasma were
monitored by a very sensitive radioassay7,8. Leucovorin ‘rescue’ (15 mg/rn2 every6hr) was started 24
hours post MIX infusion and continued till the levels of MTX dropped below 1x107 M.
Experimental methods
A. Immuno-precipitation of plasma proteins: In order to determine that the circulating MTX was bound
to which type of plasma protein, 0.5 ml of patients plasma sample obtained 9 days following the second
infusion of MDC was dialyzed extensively against normal saline at 4°C for 24 hours. Twenty five ul
from the dialyzed plasma was used to set up each immune reaction. Three different immune reactions
were set up each containing 25 ul of dialyzed plasma and 225 ul of 0.006M citrate buffer, pH 7.4. Then
250 ul of anti-human albumin or anti-human a1 acid glycoprotein or anti-human IgG was added to
respective tubes. Appropriate control reactions were also set up. These contained 25 ul of normal saline
with free MDC equal to the amount in the dialyzed patient’s plasma, 250u1 of antibody to a plasma
protein (anti-human albumin or anti-a1 acid glycoprotein or anti-human IgG) in a total volume of 0.5
ml made up with 0.006 M citrate buffer, pH 7.4. All reactions including controls were incubated at 4°C
for 48 hours and then centrifuged at 3,000 rpm at 4°C for 15 min. The supernatant solutions were
discarded and the precipitate in each tube was quickly washed with 0.5 ml of cold saline. The
precipitate was then dispersed in 250/41 of 0.006M citrate, p11 7.4, and boiled for 5 mi to extract MDC
which was then assayed by the radioassay7,8.
Gel-filtration of patient’s plasma
One ml of patient’s plasma obtained 30 hours after the third MDC infusion was applied to a column
(1.5 cmx75 cm) of sephadex G-75 as described earlier9. The sample was eluted with 0.05 M Tris-HCl
buffer, pH 7.2 at a flow rate of 12 mI/hr. One ml fractions were collected and MIX in every other
fraction was monitored by the radioassay. Dcxtran blue, human serum albumin and 3H2o were used as
column markers in a separate run on the gel.
Additional binding of [3H]MTX
Since most plasma proteins are non-specific binders of MDC additional binding of [ H]MTX at pH 7.2
by patient’s plasma was carried out according to the method described previously10 with the difference
that 50/41 plasma was used as binder instead of L1210 cytosol and incubation of the reactions was
carried out for 1 hour at 37°C.
Serum electrophoresis
Electrophoresis of two serum samples of the patient before and after second MDC infusion was carried
out according to Beckman Paragon Electrophoresis system SPE (Beckman Instruments Inc., Brea, CA).
The agarose gel after the electrophoresis was dried into a film which was then scanned in a Beckman
(Appraise) densitometer.
RESULTS AND DISCUSSION 
Figure 1 shows the decay curves of plasma MTX after 6 hr infusions (18.7 gms MTX in each infusion).
The elimination of the drug during all three infusions appears to be biphasic during the first 48 hr.
Initial phase of elimination half-lives (t1/2a) during the first and second infusions was calculated to be
1.5 hr - 2 hr while the second phase of elimination (t1/2B) was found to be approximately 5 hr. .6 hr.
These half-life values were not much different from those reported by us previously and by other
investigators11-13. However, during the third infusion, there was a substantial change in elimination
half-lives of the drug. The t1/2a value was 3.5 hr - 4 hr while t1/2B value turned was more than 12 hr
since binding of a drug to plasma proteins has been known to significantly influence, its
pharmacodynamic properties and pharmacokinetic parameters, this slower plasma clearance of MTX
following third infusion was attributed to be due to its binding to a plasma protein14,15. This binding of
the drug to the plasma protein must be strong enough so that it does not come off very easily. Different
samples of the plasma taken at different time intervals following MDC infusions were analyzed for
their ability to bind [3HJMTX.
Figure 2 shows additional binding of [3H]MTX by patient’s plasma before and after first, second and
third MDC infusions, it is evident that following second infusion, there appears something in plasma
that can bind [3]MTX more avidly and this binder of MDC persists in plasma even 16 days post third
infusion. To find out the exact nature of this binder of MTX, patient’s plasma obtained after second
infusion was extensively dialyzed against normal saline and then treated with anti-human IgG, anti-
human a1 acid glycoprotein and anti-human albumin in separate reactions.
Table shows that the bound MTX in patient’s plasma was complexed with albumin. Further
confirmation of this observation was obtained by subjecting patient’s plasma (following third course of
MTX therapy) to Sephadex G-75 gel- filtration chromatography (Figure 3).
There is a single peak of MDC bound to a protein which appears to have a size nearly that of human
serum albumin. Immunoprecipitation of 0.5 ml of fraction 65 (in the peak region) with anti-human
albumin (1 ml) revealed MTX-albumin complexes in the peak (solid bar in Figure 3) lending further
support to the notion that it is the albumin to which MDC has been bound in patient’s serum. Non-
specific binding of MDC to human serum albumin has been known for quite some time. However this
binding is quite weak with two binding constants, 8.88 mM-1 and 17.6mM-1 respectively15. The
binding of MDC to albumin in patient’s plasma following second infusion is relatively stronger as a
significant portion of the drug did not come off during dialysis of the sample (Table). Moreover,
[3H]MTX bound to it did not come off with activated charcoal used in our radioassay (Figure 2). We
are not sure whether this increased binding of MTX to patient’s plasma is due to induction of albumin
with high affinity for MDC or modification of a fraction of albumin to a high affinity form, however,
serum proteins profiles of the patient’s serum samples (before and after the second infusion) following
electrophoresis (Figure 4)
show that there is hardly any difference in the levels of albumin in these two samples. It is the property
of a non-specific binder that it binds more of a drug at higher concentrations of the drug in the reaction.
The binding of MDC to albumin before as well as after second infusion of the drug is of non-specific
nature.
Figure 5 shows that I3H]IMTX binding by the two plasma samples progressively increases as MDC
concentration in the reaction is increased from 13.75 nM-110nM. This indicates that albumin present in
plasma before second infusion and after second infusion binds MDC non-specifically, though there is
increased capacity of the second sample (after second infusion) to bind MDC and this perhaps is the
reason for delayed plasma clearance of MDC in this patient In general, delayed clearance of the drug
has been considered to be due to compromised renal function13. This report suggests that in certain
patients during the course of treatment, certain plasma proteins may undergo a change leading to
increased binding of MDC to plasma. This would delay the clearance of the drug resulting into severe
clinical toxicity.
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